

Table 4 Data used for variables in the TRIVAC model to estimate programme costs of pneumococcal conjugate vaccine-13

Variable	Estimate	Scenario		Source/s
		High	Low	
<i>Projected vaccine price per dose (US\$)</i>				
2014	20.00	35.00	14.24	Local representative of the manufacturer
2015	18.00	31.50	12.82	Derived from TRIVAC
2016	16.20	28.35	11.53	Derived from TRIVAC
2017	14.58	25.52	10.38	Derived from TRIVAC
2018	13.12	22.96	9.34	Derived from TRIVAC
2019	11.81	20.67	8.41	Derived from TRIVAC
2020	10.63	18.60	7.57	Derived from TRIVAC
2021	9.57	16.74	6.81	Derived from TRIVAC
2022	8.61	15.07	6.13	Derived from TRIVAC
2023	7.75	13.56	5.52	Derived from TRIVAC
<i>Other vaccine dose costs</i>				
International handling (% of vaccine price)	3.0	NA	NA	TRIVAC assumption (15)
International delivery (% of vaccine price)	2.0	NA	NA	TRIVAC assumption (15)
Wastage (e.g. % of doses discarded)	5.0	NA	NA	TRIVAC assumption (15)
<i>Incremental system cost of introduction per dose (US\$)</i>	1.05	NA	NA	Calculated

NA = not applicable.